News | Drug-Eluting Balloons | June 19, 2020

iVascular Launches Essential Pro Coronary Drug-coated Balloon

iVascular Launches Essential Pro Coronary Drug-coated Balloon

June 19, 2020 — iVascular SLU announced the global launch of Essential Pro, a novel coronary artery drug-coated balloon (DCB).

The Essential Pro DCB presents several platform improvements from its predecessor such as:
    • Superior safety with fast deflation times due to an increase of the inflation channel and the availability of two different shafts.
    • Better pushability due to an improved transition lumen structure that transmits the whole push to the distal shaft, and uniform transmission due to a new straight distal dual layer shaft design without welds.
    • Improved visibility with metallic radiopaque markers.
    • Improved trackability due to Hydrax plus, iVascular proprietary hydrophilic coating technology. Hydrax plus is applied in the distal shaft, reducing friction during navigation.

The Eessential Pro is indicated for the dilatation of stenosis or coronary artery or bypass grafts occlusions, including small vessels, as well as for residual stenosis after treatment with balloon or endoprosthesis and pre- and post-dilation of coronary endovascular prosthesis.
 

Clinical Study in Small Vessels Using Drug-coated Balloon

An observational, prospective and multicenter registry in small vessels. Baseline characteristics showed a very small diameter of reference (<2.5mm) and high-risk patients (56% diabetics) with only a 12.7% of bailout stenting. In this registry, essential shows a 4.2% TLF at 12-months as a primary endpoint and 9.9% MACE at 12-month as a secondary endpoint. essential demonstrates to be a reliable alternative for small coronary vessels.[1]

Essential DCB Use in Stent Restenosis

An investigator initiated, observational, prospective and multicenter study. DES restenosis was treated in 67% of the cases and a 94% of DCB angiographic success was achieved with only 2 additional stenting. In this study essential shows a 51.4% In-segment maximal area stenosis at 6-month as a primary endpoint and a 13.3% TLF at 24-month as a secondary endpoint. In this study, essential showed a good and sustained efficacy in the treatment of ISR (mostly of DES) maintained on the very long-term.[2]
 
 
For more information: ivascular.global/coronary/essentialpro/
 

References:

1. Rosa Alba Abellas-Sequeiros, Rodés-Cabau J., et al. Percutaneous Coronary Intervention for Treating De-Novo Lesions in Small Coronary Vessels: Initial Experience With the Essential Paclitaxel-Coated Balloon. Coronary Artery Disease. 29(6):477 481, September 2018.

2. J. De La Torre Hernández. Angiography and Optical Coherence Tomography Assessment of the Drug-Coated Balloon ESSENTIAL for the Treatment of In-Stent Restenosis. Cardiovasc Revasc Med. 2019 Jul 23. pii: S1553-8389(19)30433-6.

 
 

Related Content

News | Cath Lab

May 26, 2022 — The U.S. Food and Drug Administration (FDA) has recalled the Dragonfly OpStar Imaging Catheter, and has ...

Home May 26, 2022
Home
News | Cath Lab
April 25, 2022 – NewYork-Presbyterian Hudson Valley Hospital celebrated the launch of its interventional cardiology ...
Home April 25, 2022
Home
News | Cath Lab
April 18, 2022 – Royal Philips and Oulu University Hospital (Finland) have announced a strategic 10-year partnership ...
Home April 18, 2022
Home
News | Cath Lab
February 16, 2022 – Fremont Bank Foundation recently donated $750,000 to its community partner, St. Rose Hospital ...
Home February 16, 2022
Home
News | Cath Lab
February 14, 2022 — A collaborative effort between The Valley Heart and Vascular Institute’s cardiology team ...
Home February 14, 2022
Home
Sponsored Content | Videos | Cath Lab

Advancements in analytics and data visualizations are helping to streamline operations and improve productivity at cath ...

Home January 13, 2022
Home
News | Cath Lab

January 4, 2022 — The U.S. Food and Drug Administration (FDA) has authorized marketing of the first laser-based device ...

Home January 04, 2022
Home
News | Cath Lab

December 14, 2021 — RSIP Vision, a medical imaging company applying advanced artificial intelligence (AI) and computer ...

Home December 14, 2021
Home
Feature | Cath Lab

November 15, 2021 — RealView Imaging Ltd. recently received FDA 510(k) clearance for its Holoscope-i holographic system ...

Home November 15, 2021
Home
News | Cath Lab

November 10, 2021 — Shockwave Medical a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely ...

Home November 10, 2021
Home
Subscribe Now